...
首页> 外文期刊>American Family Physician >Perioperative cardiac risk reduction
【24h】

Perioperative cardiac risk reduction

机译:降低围手术期心脏风险

获取原文
获取原文并翻译 | 示例

摘要

Cardiovascular complications are the most common cause of perioperative morbidity and mortality. Noninvasive stress testing is rarely helpful in assessing risk, and for most patients there is no evidence that coronary revascularization provides more protection against perioperative cardiovascular events than optimal medical management. Patients likely to benefit from perioperative beta blockade include those with stable coronary artery disease and multiple cardiac risk factors. Perioperative beta blockers should be initiated weeks before surgery and titrated to heart rate and blood pressure targets. The balance of benefits and harms of perioperative beta-blocker therapy is much less favorable in patients with limited cardiac risk factors and when initiated in the acute preoperative period. Perioperative statin therapy is recommended for all patients undergoing vascular surgery. When prescribed for the secondary prevention of cardiovascular disease, aspirin should be continued in the perioperative period.
机译:心血管并发症是围手术期发病和死亡的最常见原因。无创压力测试很少有助于评估风险,对于大多数患者,没有证据表明冠脉血运重建比最佳医疗管理能够更好地防止围手术期心血管事件。可能受益于围手术期β受体阻滞的患者包括那些患有稳定的冠状动脉疾病和多种心脏危险因素的患者。围手术期β受体阻滞剂应在手术前几周开始,并调整至心率和血压目标。围手术期β受体阻滞剂治疗的利弊平衡在心脏危险因素有限的患者以及在急性术前期开始治疗时不利。建议对所有接受血管外科手术的患者进行围手术期他汀类药物治疗。如果开处方用于心血管疾病的二级预防,则围手术期应继续服用阿司匹林。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号